Aimin Zang

793 total citations
47 papers, 428 citations indexed

About

Aimin Zang is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Aimin Zang has authored 47 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Molecular Biology and 15 papers in Cancer Research. Recurrent topics in Aimin Zang's work include Cancer Immunotherapy and Biomarkers (10 papers), MicroRNA in disease regulation (9 papers) and Cancer-related molecular mechanisms research (9 papers). Aimin Zang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), MicroRNA in disease regulation (9 papers) and Cancer-related molecular mechanisms research (9 papers). Aimin Zang collaborates with scholars based in China, Germany and Greece. Aimin Zang's co-authors include Youchao Jia, Wufang Fan, Jinchao Zhang, Yanhong Shang, Zhuoqi Zhang, Qun Zhao, Kun Ge, Liqiao Fan, Bibo Tan and Bei Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Aimin Zang

40 papers receiving 422 citations

Peers

Countries citing papers authored by Aimin Zang

Since Specialization

Citations

This map shows the geographic impact of Aimin Zang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimin Zang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimin Zang more than expected).

Fields of papers citing papers by Aimin Zang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimin Zang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimin Zang. The network helps show where Aimin Zang may publish in the future.

Co-authorship network of co-authors of Aimin Zang

This figure shows the co-authorship network connecting the top 25 collaborators of Aimin Zang. A scholar is included among the top collaborators of Aimin Zang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimin Zang. Aimin Zang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	19P: Subgroup analysis of first-line camrelizumab plus chemotherapy in brain metastases of NSCLC: Results from the CTONG 2003 trial 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), Qingzhao Yu, Qian Bu, (unknown), Feng Ning, Gang Wu, Galvin Sim Siang Lin, Aimin Zang, Shaohua Ma, Caicun Zhou, Albert Liu, Yuanyuan Zhao, Cheng Wang, (unknown), Gwan Hee Han, Jun Zhao, (unknown), Jun Lv, Yi‐Long Wu	1
2	Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer 2024 ·Cancer Medicine ·(unknown), Xuefei Li, Lin Wu, Guohua Yu, Aimin Zang, (unknown), Jinsheng Shi, Ligong Nie, (unknown), Jian Fang	2
3	Overexpression of ornithine decarboxylase 1 mediates the immune-deserted microenvironment and poor prognosis in diffuse large B-cell lymphoma 2024 ·SHILAP Revista de lepidopterología ·(unknown), Jia Guo, Xiaofang Wang, (unknown), (unknown), Haiying Chen, (unknown), Zhihao Jin, Changdong Lin, Aimin Zang, Youchao Jia, Lin Feng, Liang Wang	0
4	A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy 2024 ·Cancer Medicine ·Yuguang Zhao, Xiao Chen, Jun Yao, Jianlin Long, Yong Mao, Di Wu, Aimin Zang, Jun Zhao, Ziling Liu, (unknown), Ye Chen, (unknown), Qun Guo, Li Li, Jiuwei Cui	4
5	540P Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup 2023 ·Annals of Oncology ·Caicun Zhou, Yi Hu, Kejing Ying, Fei Xu, Lin Wu, Xinhua Wang, Hongru Sun, Feng Luo, Jinpeng Shi, Aimin Zang, Yu Pan, Zhendong Chen, Zhenyu Jia, Pei‐Hua Lu, Li Zhang, Ying Cheng, Kang Wang, Qun Wang, Jiayuan Li, (unknown)	1
6	385MO A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors 2023 ·Annals of Oncology ·Jian Zhang, (unknown), Yan Du, Ya Meng, Yunpeng Liu, Yehui Shi, Jie Wang, Aimin Zang, Shanzhi Gu, Tianshu Liu, Huadong Zhou, (unknown), (unknown), Xiang Zhang, (unknown), Mingzhong Li	2
7	519P Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC) 2023 ·Annals of Oncology ·Ying Cheng, (unknown), (unknown), Yan Yu, Aimin Zang, (unknown), Dongqing Lv, Shuang Li, Zhijun Meng, Jian Zhang, Qisen Guo, Dingzhi Huang, (unknown), Jing Liu, Weidong Mao, (unknown), Ying Zhang, En Chen, Zhi Wang, (unknown)	4
8	Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroup (127) 2022 ·Gynecologic Oncology ·Dong Wang, (unknown), Aimin Zang, Jing Wang, (unknown), Lin Shen, Jian Li, (unknown), Tianshu Liu, Yanhong Deng, Yaling Xu, (unknown), (unknown), (unknown)	0
9	SEMA3D Plays a Critical Role in Peptic Ulcer Disease-Related Carcinogenesis Induced by H. pylori Infection 2022 ·SHILAP Revista de lepidopterología ·Zhiyu Wang, (unknown), Lin An, Kunjie Wang, (unknown), Yan Shi, Aimin Zang, (unknown), Wenwen Li	2
10	LncRNA MCM3AP-AS1 Downregulates LncRNA MEG3 in Triple Negative Breast Cancer to Inhibit the Proliferation of Cancer Cells 2021 ·Critical Reviews in Eukaryotic Gene Expression ·(unknown), (unknown), (unknown), Aimin Zang, Bin Liu, Ling Hu, Lin Jia, (unknown), Lin Yang, (unknown)	5
11	840P Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma 2021 ·Annals of Oncology ·(unknown), Yanru Qin, (unknown), (unknown), (unknown), Aimin Zang, Lijuan Yang, Derek Lin, (unknown), Huilian Zhu, Renbin Zhao	2
12	1339P Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: A randomized, double-blind, multicenter phase III study 2021 ·Annals of Oncology ·J. Wang, Ran Wang, Xiaorong Dong, (unknown), Yan Yu, Sen Yang, (unknown), (unknown), Yueyin Pan, (unknown), Chengzhi Zhou, Wei Hong, Hui Zhao, Yang Liu, Lingxia Huang, Rong Wu, Aimin Zang, Rui Ma, Lin Wu, Dongqing Lv	1
13	Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis 2021 ·BioMedical Engineering OnLine ·Yumiao Li, Xiaoxue Yu, Yuhao Zhang, Xiaofang Wang, (unknown), Dan Liu, (unknown), Xiangpeng Gao, (unknown), Aimin Zang, Youchao Jia	7
14	TGF-β1 suppresses proliferation and promotes apoptosis in colon cancer cell by inactivating ERK pathway 2020 ·Panminerva Medica ·Hua Yang, (unknown), Yang Yang, Qian Zhang, Youchao Jia, Aimin Zang, Lili Ren	3
15	Inducible T-cell co-stimulators regulate the proliferation and invasion of human hepatocellular carcinoma HepG2 cells 2018 ·Biological Research ·(unknown), Yanan Wang, Aimin Zang, Yanhong Shang, (unknown), Zhiyu Wang, Yangyang Wang, Hua Yang	3
16	Comparison of application value between CEUS and conventional ultrasound in preoperative and staging diagnosis of cervical cancer 2016 ·Biomedical Research-tokyo ·Lixia Liu, Jianhui Li, Aimin Zang, (unknown), Ping Wang, Bin Liu	1
17	miRNA-486 and miRNA-499 in human plasma evaluate the clinical stages of lung cancer and play a role as a tumor suppressor in lung tumorigeneisis not pathogenesis 2016 ·Bangladesh Journal of Pharmacology ·(unknown), Aimin Zang, (unknown), Xiaofang Li, Ke Zhang, (unknown), Ruiyao Wang, (unknown), (unknown)	2
18	Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling 2016 ·Oncology Letters ·Yang� Yang, Aimin Zang, (unknown), Yanhong Shang, Zhuoqi Zhang, Kun Ge, Jinchao Zhang, Wufang Fan, Bei Wang	54
19	Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling 2016 ·International Journal of Oncology ·Youchao Jia, Zhigang Wang, Aimin Zang, Shunchang Jiao, Sumei Chen, Yan Fu	29
20	Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21 2016 ·Molecular Medicine Reports ·Xiaofang Li, Aimin Zang, Youchao Jia, Jinchao Zhang, Wufang Fan, (unknown), (unknown), Lei Zhang, (unknown), (unknown), Xiaowei Zhu	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact